Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts?

Core Insights - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a promising biotech stock with significant growth potential [1] - The company reported total revenues of $825 million in fiscal Q2 2025, reflecting a 16% year-over-year increase and a 17% increase at constant currency [1] - GAAP diluted earnings per share (EPS) for the quarter reached $1.23 [1] Analyst Ratings - Christopher Raymond from Raymond James maintained a Buy rating on BioMarin and set a price target of $85.00 [2] - Wedbush's Yun Zhong also assigned a Buy rating for the stock, indicating positive sentiment [3] - H.C. Wainwright initiated coverage with a Hold rating and a price target of $60 [3] Product Pipeline - BioMarin develops therapies for serious and life-threatening medical conditions and rare diseases [4] - The company's product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [4]